Suraksha Diagnostic Limited has scheduled a meeting of its Board of Directors for Thursday, May 21, 2026. The meeting will be held at the company's registered office to discuss and approve the audited financial results for the quarter and financial year ended March 31, 2026.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the audited standalone and consolidated financial results for the fourth quarter and the full financial year ending March 31, 2026. Additionally, the board will deliberate on the recommendation of a dividend, if any, on equity shares for the financial year ended March 31, 2026.

Trading Window Closure

In accordance with the company's Internal Code of Conduct for Prohibition of Insider Trading, the trading window for dealing in the securities of the company was closed on April 1, 2026. This closure affected all directors, Key Managerial Personnel (KMPs), designated persons, employees, connected persons, and their immediate relatives.

The trading window is scheduled to reopen after the expiry of 48 hours from the date of declaration of the financial results. This measure is in line with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Key Details

The intimation regarding the board meeting was submitted to BSE Limited and The National Stock Exchange of India Limited on May 13, 2026. The company has also made this information available on its official website.

Suraksha Diagnostic Limited has formally declared that its promoters and promoter group members have not encumbered any shares held in the company during the financial year ended 31 March 2026. The declaration, submitted on 03 April 2026, was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The confirmation was provided by Dr. Somnath Chatterjee on behalf of all promoters, promoter groups, and persons acting in concert (PAC).

The disclosure was addressed to the stock exchanges, including BSE Limited and the National Stock Exchange of India (NSE), with the scrip code 544293 and symbol SURAKSHA. The promoters confirmed that no shares were encumbered directly or indirectly, other than those already disclosed during the specified financial year. This move ensures transparency and adherence to regulatory requirements.

Promoter Group Details

The declaration includes a comprehensive list of promoters and promoter group members, as outlined in Annexure-A. The key promoters include Dr. Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma, each accompanied by their respective promoter group members. Below is a summary of the promoter structure:

Entities in the Promoter Group

Annexure-B lists 62 entities forming part of the promoter group, including companies like Dneema Overseas Private Limited, Tinni Investments Limited, and Oscar International Limited. The list also includes various LLPs and HUFs, such as Terriific Infracon LLP and Bipul Mittal HUF. These entities are integral to the promoter group structure of Suraksha Diagnostic Limited.

The declaration was signed by Dr. Somnath Chatterjee, Promoter of Suraksha Diagnostic Limited, and copies were sent to the Audit Committee and the Company Secretary & Compliance Officer for record-keeping. This filing underscores the company's commitment to regulatory compliance and transparency in its shareholding patterns.